Breakout Bulletin: July 20-July 24

You’re busy. Between patients, prior authorizations, inbox messages, and everything else on your plate, keeping up with the literature is the first thing that slips. Dermatology Times NP/PA Connect is here to make sure it doesn’t. Each week, we pull the most clinically relevant news from across dermatology and bring it straight to your inbox — what’s new, what it means, and what’s worth watching. This week: New York locks in independent practice authority through 2030, psoriasis patients show silent heart damage even when their skin looks fine, nonsteroidal topicals only help if patients can actually access them, and a head-to-head trial pits finasteride against dutasteride for androgenetic alopecia.

New York Locks In NP Independent Practice Through 2030

Gov Kathy Hochul signed an extension on May 28, 2026, pushing the sunset date on New York's NP independent practice framework from July 1, 2026, to July 1, 2030. NPs with more than 3600 hours of practice can continue seeing patients without a written collaborative agreement or protocol tied to a physician. NPs below that threshold still need a formal collaborative arrangement with a physician in the relevant specialty.

Companion bills S2360 and A1220, which would eliminate the sunset clause entirely and let experienced NPs supervise those still accruing hours, remain in committee.¹² Until either bill moves, the 2030 expiration date is the operative deadline for practices to track.

This legislation improves healthcare access for New York residents, especially in rural and economically disadvantaged areas facing severe physician shortages.— Lakshi Aldredge, MSN, ANP-BC, DCNP

▶ Why it matters: If you practice in New York, the immediate compliance deadline is off the table, but the underlying authority is still tied to an expiration date, not permanence. Watch S2360 and A1220 if you want to see this settled for good.

MORE ON PRACTICE MANAGEMENT

Psoriasis Patients Have Silent Heart Damage Even When Skin Looks Fine

The PSOCADIA study used transthoracic echocardiography, including global longitudinal strain (GLS), to compare 1010 adults with psoriasis against 1010 matched controls. Abnormal GLS below 16% turned up in 16.7% of patients with psoriasis versus 6.0% of controls, and the association held after adjusting for traditional cardiovascular risk factors.³

Myocardial dysfunction was just as common in patients with mild psoriasis as in those with moderate to severe disease, so skin severity alone is not a reliable proxy for cardiac risk. Higher body mass index and diabetes were the strongest predictors within the psoriasis group. Because the design is cross-sectional, the data show association, not causation.

▶ Why it matters: Order cardiovascular risk screening based on the diagnosis of psoriasis itself, not on how clear or involved the skin appears at a given visit.

MORE ON PSORIASIS

Nonsteroidal Topicals Only Work If Patients Can Actually Get Them

In the closing installment of a Dermatology Times video series, faculty built on a consensus statement about affordable access to argue that advanced nonsteroidal topical therapies are only as good as a practice's ability to get patients through insurance hurdles.⁴ Panelists pointed to dermatology-focused specialty pharmacies, manufacturer assistance programs, and dedicated patient support services as the levers that most reliably overcome prior authorization denials and formulary restrictions.

The faculty were direct that these agents are not meant to replace topical corticosteroids outright. Framed as tools for corticosteroid stewardship, nonsteroidal options let clinicians reduce cumulative steroid exposure while still controlling disease over the long term.

▶ Why it matters: Build a specialty pharmacy referral and a manufacturer assistance check into your workflow before you prescribe a nonsteroidal topical, not after the denial comes back.

Finasteride and Dutasteride Perform Nearly Identically for AGA, but Watch PSA

A randomized, single-blind trial from Iran followed 46 men aged 20 to 50 years with moderate to severe androgenetic alopecia for 24 weeks on either finasteride 1 mg daily or dutasteride 0.5 mg daily. Trichoscopy, standardized photography, and patient satisfaction scores all showed comparable hair growth gains between the two drugs, with no statistically significant difference between arms.⁵

Dutasteride produced a significantly larger drop in prostate-specific antigen, consistent with its broader inhibition of 5-alpha-reductase activity. Liver function stayed stable in both arms, and sexual adverse effects, mainly erectile dysfunction and reduced libido, were the most common complaints in both groups but were generally mild. This was a small, single-center trial, so treat the equivalence finding as directional rather than definitive.

▶ Why it matters: Either drug is a reasonable first choice for AGA, but factor dutasteride's larger PSA suppression into any conversation about prostate cancer screening in patients on that regimen.

MORE ON ALOPECIA

Should Aesthetic Training Require Primary Care Experience First

Lori J. Robertson, MSN, PHN, APRN, FNP-C, argued in a brief report that primary or acute care experience should be a prerequisite for entering aesthetic medicine, not an optional bonus.⁷ She illustrated the point with 2 cases from her own practice: a 46-year-old man who arrived for neuromodulator treatment and turned out to have adenocarcinoma of the jugulodigastric gland, and a 52-year-old woman seeking treatment for facial volume loss whose asymmetric globe prominence led to a hyperthyroidism diagnosis and thyroid eye disease workup.

Robertson also proposed a national certifying body for aesthetic medicine, since no single organization currently verifies baseline medical competency across nursing, physician associate, and physician pathways into the field.

A robust background in primary or acute care should be a recognized prerequisite.— Lori J. Robertson, MSN, PHN, APRN, FNP-C

MORE ON AESTHETICS

▶ Why it matters: A cosmetic consult is still a full patient encounter. Robertson's cases are a reminder to keep a systemic review of systems in the visit even when the chief complaint is purely cosmetic.

References:

1. Heaning S. New York extends nurse practitioner independent practice authority through 2030. Dermatology Times. Published July 20, 2026. https://www.dermatologytimes.com/view/new-york-extends-nurse-practitioner-independent-practice-authority-through-2030
2. New York bills seek to extend APRN independence. American Med Spa Association. Updated June 4, 2026. https://www.americanmedspa.org/legal-updates/new-york-bills-seek-to-extend-aprn-independence/
3. Dons M, Sengeløv M, Skaarup KG, et al. Cardiac structure and function in psoriasis: A cross-sectional analysis of the PSOCADIA study. J Eur Acad Dermatol Venereol. Published online July 17, 2026. doi:10.1111/jdv.70609
4. Golant AK. Improving access to advanced nonsteroidal topical therapies in inflammatory dermatoses. Dermatology Times. Accessed July 22, 2026. https://www.dermatologytimes.com/view/improving-access-to-advanced-nonsteroidal-topical-therapies-in-inflammatory-dermatoses
5. Poostiyan N, Nikyar Z, Makhmali R, Hosseini M, Shahmoradi Z. Efficacy and safety of oral finasteride versus dutasteride in moderate-to-severe androgenetic alopecia in males based on trichoscopic and laboratory findings: A clinical comparison in Iran. J Dermatolog Treat. 2026;37(1):2583849. doi:10.1080/09546634.2025.2583849
6. Altamirano-Jara JB, Acosta-España JD, Zambrano LI, Rodriguez-Morales AJ. The dermatologic burden of flooding: A systematic review of epidemiology, clinical manifestations, and management in a warming world. Int J Dermatol. Published online July 17, 2026. doi:10.1111/ijd.70562
7. Robertson LJ. The non-negotiable prerequisite: Why primary or acute care experience is foundational for aesthetic providers. J Clin Aesthet Dermatol. 2026;19(5-6 Suppl 1):S24-S26.